ReviewBiomolecules2024
Cellular and Molecular Mechanisms of Hypertrophy of Ligamentum Flavum.
Review in Biomolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07232836 (The Role of Cytokines and Neuroplasticity Modulators in the Development of Spinal Canal Stenosis and the Identification of Biomarkers for the Biochemical Evaluation of Treatment in Patients Undergoing Endoscopic Spinal Canal Decompression), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Role of Cytokines and Neuroplasticity Modulators in the Development of Spinal Canal Stenosis and the Identification of Biomarkers for the Biochemical Evaluation of Treatment in Patients Undergoing Endoscopic Spinal Canal Decompression
Who cites it
14 citing papers in PubMed.
- Lumbar spinal stenosis in axial spondyloarthritis and chronic low back pain: a cross-sectional magnetic resonance imaging study with clinical dimensions.Clinical rheumatology · 2026Article
- The Main Immune Markers of Ligamentum Flavum Hypertrophy: A Narrative Literature Review.International journal of molecular sciences · 2026Review
- Prioritization of Candidate miRNA Regulators Targeting Fibrotic-Immune Remodeling in Ligamentum Flavum Hypertrophy: An Integrated mRNA-miRNA Transcriptomic Study.Biomedicines · 2026Article
- Article
- Integrated molecular, microRNA, and biochemical profiling reveals oxidative stress-driven degeneration of the ligamentum flavum in lumbar spinal stenosis.Scientific reports · 2026Article
- Impact of Menopause and Associated Hormonal Changes on Spine Health in Older Females: A Review.Cells · 2026Review
- Prevalence and Demographic Associations of Ligamentum Flavum Hypertrophy in Lumbar Spinal Stenosis.Orthopedic research and reviews · 2026Article
- From mechanotransduction to manual therapy: advances in piezo/TRP channels and lumbar degeneration.Frontiers in physiology · 2026Review
- Integrated bioinformatic analysis of biomarkers, pathways, and immune cell infiltration in ossification of the ligamentum flavum.International journal of clinical and experimental pathology · 2026Article
- Multi-Omics Bioinformatic Analyses Linking LOXL4 with Spondylolisthesis.Orthopedic research and reviews · 2026Article
- Targeting transthyretin deposition in lumbar spinal stenosis: a mechanistic rationale for tafamidis.Frontiers in surgery · 2026Article
- Changes in the Concentration Profile of Selected Micro- and Macro-Elements in the Yellow Ligament Obtained from Patients with Degenerative Stenosis of the Lumbo-Sacral Spine.Journal of clinical medicine · 2025Article
- Electroacupuncture in non-surgical management of lumbar spinal stenosis: mechanistic potential in attenuating ligamentum flavum thickening via inflammatory factor modulation.Frontiers in immunology · 2025Review
- Single-cell RNA-seq uncovers lineage-specific regulatory alterations of fibroblasts and endothelial cells in ligamentum flavum hypertrophy.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Hypertrophy of the ligamentum flavum (HLF) is a common contributor to lumbar spinal stenosis (LSS). Fibrosis is a core pathological factor of HLF resulting in degenerative LSS and associated low back pain. Although progress has been made in HLF research, the specific molecular mechanisms that promote HLF remain to be defined. The molecular factors involved in the onset of HLF include increases in inflammatory cytokines such as transforming growth factor (TGF)-β, matrix metalloproteinases, and pro-fibrotic growth factors. In this review, we discuss the current understanding of the mechanisms involved in HLF with a particular emphasis on aging and mechanical stress. We also discuss in detail how several pathomechanisms such as fibrosis, proliferation and apoptosis, macrophage infiltration, and autophagy, in addition to several molecular pathways involving TGF-β1, mitogen-activated protein kinase (MAPKs), and nuclear factor-κB (NF-κB) signaling, PI3K/AKT signaling, Wnt signaling, micro-RNAs, extracellular matrix proteins, reactive oxygen species (ROS), etc. are involved in fibrosis leading to HLF. We also present a summary of the current advancements in preclinical animal models for HLF research. In addition, we update the current and potential therapeutic targets/agents against HLF. An improved understanding of the molecular processes behind HLF and a novel animal model are key to developing effective LSS prevention and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.